OUTCOMES COMMITTEE AGENDA

开发药理学核心将开发和实施以下试验： 艾滋病患者使用的药物。 这些试验将用于执行 药代动力学和药物相互作用研究，具有确定 药物处置和相互作用的机制，并提供临床 最佳治疗方案设计指南。 这个网站将 对这些研究保持积极和灵活的态度;即， 尽管我们计划了具体的项目，但新项目的可用性很可能 药物将为重要的研究提供机会， 预计在这个时候。 具体目标包括： 1)评估DDI肾排泄的决定因素。 2)评估ACT和DDI对彼此的药代动力学影响。 3)评估DDI在肾功能不全患者中的消除情况。 4)8-氨基喹诺酮类药物在HIV阳性患者体内的药代动力学研究 患者 5)评估艾滋病患者药物代谢表型。 6)评估患者使用药物的立体选择性药代动力学 艾滋病

The Developmental Pharmacology Core will develop and implement assays for drugs used in patients with AIDS. These assays will be utilized to perform pharmacokinetic and drug interaction studies with dual goals of determining mechanisms of drug disposition and interaction and of providing clinical guidelines for design of optimal therapeutic regimens. This site will maintain a dynamic and flexible posture towards such studies; namely, though we plan specific projects, it is likely that availability of new drugs will provide the opportunity for important studies that cannot be anticipated at this time. Specific aims include: 1) To assess the determinants of renal excretion of DDI. 2) To assess the pharmacokinetic effects of ACT and DDI on each other. 3) To assess the elimination of DDI in patients with renal insufficiency. 4) To assess the pharmacokinetics of 8-aminoquinolones in HIV positive patients. 5) To assess phenotypes of metabolism of drugs used in patients with AIDS. 6) To assess stereoselective pharmacokinetics of drugs used in patients with AIDS.